Our primary aim was to examine and compare plasma NfL and GFAP levels in the pre-diagnostic phase of multiple neurodegenerative diseases, including Alzheimer’s disease, parkinsonian syndromes, and ALS, investigating their associations with each other and with incident neurodegenerative diseases. The gene discussed is GFAP; the disease is neurodegenerative disease.